208 related articles for article (PubMed ID: 20362478)
1. TEThered to Runx: novel binding partners for runx factors.
Li X; Decker M; Westendorf JJ
Blood Cells Mol Dis; 2010 Jun; 45(1):82-5. PubMed ID: 20362478
[TBL] [Abstract][Full Text] [Related]
2. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.
Li X; McGee-Lawrence ME; Decker M; Westendorf JJ
J Cell Biochem; 2010 Nov; 111(4):933-43. PubMed ID: 20665663
[TBL] [Abstract][Full Text] [Related]
3. Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors.
Li X; Hoeppner LH; Jensen ED; Gopalakrishnan R; Westendorf JJ
J Cell Biochem; 2009 Oct; 108(2):378-87. PubMed ID: 19585539
[TBL] [Abstract][Full Text] [Related]
4. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.
Cironi L; Riggi N; Provero P; Wolf N; Suvà ML; Suvà D; Kindler V; Stamenkovic I
PLoS One; 2008 Jul; 3(7):e2634. PubMed ID: 18648544
[TBL] [Abstract][Full Text] [Related]
5. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein.
Chansky HA; Hu M; Hickstein DD; Yang L
Cancer Res; 2001 May; 61(9):3586-90. PubMed ID: 11325824
[TBL] [Abstract][Full Text] [Related]
7. Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.
Ryan JJ; Sprunger ML; Holthaus K; Shorter J; Jackrel ME
J Biol Chem; 2019 Jul; 294(29):11286-11296. PubMed ID: 31171724
[TBL] [Abstract][Full Text] [Related]
8. Runt-related transcription factors impair activin induction of the follicle-stimulating hormone {beta}-subunit gene.
Breen KM; Thackray VG; Coss D; Mellon PL
Endocrinology; 2010 Jun; 151(6):2669-80. PubMed ID: 20357224
[TBL] [Abstract][Full Text] [Related]
9. The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins.
Perani M; Antonson P; Hamoudi R; Ingram CJ; Cooper CS; Garrett MD; Goodwin GH
J Biol Chem; 2005 Dec; 280(52):42863-76. PubMed ID: 16227627
[TBL] [Abstract][Full Text] [Related]
10. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes.
Bertolotti A; Melot T; Acker J; Vigneron M; Delattre O; Tora L
Mol Cell Biol; 1998 Mar; 18(3):1489-97. PubMed ID: 9488465
[TBL] [Abstract][Full Text] [Related]
11. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
Owen LA; Kowalewski AA; Lessnick SL
PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
[TBL] [Abstract][Full Text] [Related]
12. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.
Hancock JD; Lessnick SL
Cell Cycle; 2008 Jan; 7(2):250-6. PubMed ID: 18256529
[TBL] [Abstract][Full Text] [Related]
13. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma.
Eliazer S; Spencer J; Ye D; Olson E; Ilaria RL
Mol Cell Biol; 2003 Jan; 23(2):482-92. PubMed ID: 12509448
[TBL] [Abstract][Full Text] [Related]
14. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors.
Lian JB; Javed A; Zaidi SK; Lengner C; Montecino M; van Wijnen AJ; Stein JL; Stein GS
Crit Rev Eukaryot Gene Expr; 2004; 14(1-2):1-41. PubMed ID: 15104525
[TBL] [Abstract][Full Text] [Related]
15. A conserved N-terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins.
Thomsen C; Grundevik P; Elias P; Ståhlberg A; Aman P
FASEB J; 2013 Dec; 27(12):4965-74. PubMed ID: 23975937
[TBL] [Abstract][Full Text] [Related]
16. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
17. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.
Yang L; Chansky HA; Hickstein DD
J Biol Chem; 2000 Dec; 275(48):37612-8. PubMed ID: 10982800
[TBL] [Abstract][Full Text] [Related]
18. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation.
Silvany RE; Eliazer S; Wolff NC; Ilaria RL
Oncogene; 2000 Sep; 19(39):4523-30. PubMed ID: 11002425
[TBL] [Abstract][Full Text] [Related]
19. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
20. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
